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AntifungalAbstract A series of 1,3,4-oxadizole derivatives containing 1,4-benzodioxane ring system were syn-
thesized starting from 2,3-dihydro-1,4-benzodioxane-2-carbohydrazide. The synthesized com-
pounds were characterized and evaluated for antibacterial activity against Staphylococcus aureus,
Escherichia coli and Bacillus subtilis and antifungal activity against Aspergillus niger, Aspergillus ﬂa-
vus and Candida albicans by twofold serial dilution technique. Some of the synthesized compounds
displayed comparable or even better antibacterial and antifungal activities than reference drugs nor-
ﬂoxacin, chloramphenicol and ﬂuconazole, against tested strains.
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article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
In recent years, the incidence of fungal and bacterial infections
has increased dramatically. The widespread use of antifungal
and antibacterial drugs resulted in resistance to drug therapy
against fungal and bacterial infections which led to serioushealth hazards. The resistance of wide spectrum antifungal
and antibacterial agents has initiated discovery and modiﬁca-
tion of the new antifungal and antibacterial drugs.
It is well-known that azole moieties are important phar-
macophore that appear extensively in various types of phar-
maceutical agents, widely implicated in biochemical
processes and display diversity of pharmacological activities
(Mamolo et al., 2005). A large number of azole compounds
are used as antimicrobial drugs in clinic, for example, mico-
nazole, clotrimazole and econazole are administered topi-
cally, while ketoconazole, itraconazole and ﬂuconazole are
useful in the treatment of systemic infections. Furthermore,
it has been found that some azoles such as miconazole gave
remarkable antibacterial activity against methicillin-resistant
Staphylococcus aureus (MRSA) (Guven et al., 2007). The
S1030 H. Khalilullah et al.widespread use of azole antimicrobial drugs led numerous
efforts to develop some azole derivatives as new antimicro-
bial agents.
The compounds containing dioxane rings are of interest for
the introduction of a variety of substituents into common skel-
eton, novel transformations, and can provide new and general
routes to a variety of organic molecules. There are two impor-
tant characteristics of these compounds, namely (i) readily
opening to alkyletenes either under thermal or photochemical
conditions and (ii) the C–C double bond, if present in the diox-
ane ring, acts as the enol form of masked acylacetic acids,
which are important building blocks in organic syntheses. Ben-
zodioxane represents a series of synthetic and natural com-
pounds of considerable medicinal importance. Compounds
containing dioxane ring systems exhibited different biological
activities like antimicrobial (Mallesha and Mohana, 2011),
antihepatotoxic (Ahmed et al., 2003; Khan et al., 2006),
a-adrenergic blocking agent (Chapleo et al., 1983) and anti-
inﬂammatory (Vazquez et al., 1997).
Oxadiazoles are an important type of oxygen and nitrogen
containing aromatic heterocyclic compounds, possess desir-
able electronic and charge-transport properties and the
various functional groups are easily introduced into the struc-
turally rigid oxadiazole ring. These characteristics resulted in
the extensive potential applications of oxadiazole based deriv-
atives in the ﬁeld of medicinal chemistry. Various methods
have been reported recently for the synthesis of 1,3,4-oxadiaz-
oles (Adib et al., 2009; Ramazani and Rezaei, 2010;
Vechorkin et al., 2010). A large number of biological activities
are associated with oxadiazole derivatives such as antitumor
(Aboraia et al., 2006), anti-inﬂammatory (Palaska et al.,
2002; Amir and Shikha, 2004), antimicrobial (Jha et al.,
2010; Gilani et al., 2010; Manjunatha et al., 2010; El-Azab,
2007; Mamolo et al., 2005; Saleh et al., 2004),
antifungal (Chen et al., 2008) and anticonvulsant (Zarghi
et al., 2005).
In continuation to extend our research on antimicrobial
compounds, we designed a series of new 1,3,4-oxadiazole
derivatives containing 1,4-benzodioxane ring system. Herein,
we wish to report the synthesis, antibacterial and antifungal
activities of some novel 1,3,4-oxadiazole derivatives.
2. Experimental protocols
2.1. Chemistry
The IR spectra were recorded on Brucker. The mass spectra
were recorded on a Bruker daltronics high resolution mass
spectrometer, the 1H NMR (300 MHz) was recorded on Bru-
ker DPX 300 spectrometer in CD3OD and DMSO-d6 using
TMS as internal standard reference and chemical shifts are
in d ppm. Elemental analyses were performed on Elementar
Vario EL III, Carlo Erba 1108. The melting points were deter-
mined by capillary method.
2.1.1. Synthesis of ethyl-l,4-benzodioxane-2-carboxylate (1)
Anhydrous potassium carbonate (50 g) was added in portions
to a stirred solution of 55 g of catechol in 200 mL of dry ace-
tone followed by the dropwise addition of 34.5 g of ethyl-2,3-
dibromopropionate. Another 50 g of potassium carbonate and
34.5 g of the dibromoester were added similarly and this wasrepeated two times more using a total of 200 g of potassium
carbonate and 137.5 g of ester. Stirring and reﬂuxing was con-
tinued for another 15 h. The reaction mixture was then ﬁltered
and the solid was washed several times with acetone. The ﬁl-
trate was concentrated to about 75 mL and the residue was di-
luted with 50 mL of cold water. The oily layer was separated
from the aqueous layer; the latter was extracted repeatedly
with ether. The combined oily layer and ether extracts were
washed with water, dried over magnesium sulfate, and evapo-
rated. The dark residue was distilled at 96–97 C (0.1 mm/Hg)
to yield 38 g of ester 1 as a colorless semisolid. 1H NMR
(300 MHz, DMSO-d6): d ppm 1.23 (3H, t, J= 7.1 Hz, CH3-
12), 4.20 (2H, q, J= 7.1, 5.7 Hz, CH2-12), 4.30 (2H, d,
J= 2.7, CH2-3), 4.77 (1H, t, J= 2.7, CH-2), 6.84 (4H, m,
Ar-H); FTIR cm1: 3052 (‚C–H, aromatic), 1772 (C‚O),
1653 (C‚C), 1292 (C–O, ester).2.1.2. Synthesis of 2,3-dihydro-1,4-benzodioxane-2-
carbohydrazide (2)
To a solution of ethyl-1,4-benzodioxane-2-carboxylate
(0.01 mol) in ethanol (20 mL), hydrazine hydrate (0.01 mol)
was added and the reaction mixture was reﬂuxed. The progress
of the reaction was monitored by TLC. After the completion
of the reaction (usually 16 h), the excess solvent was removed
under reduced pressure. The reaction mixture was poured over
crushed ice. The solid thus separated was ﬁltered, dried and
crystallized with methanol to give a white powder; m.p.:
110–112 C; Yield: 80%; 1H NMR (300 MHz, DMSO-d6): d
ppm 3.91 (2H, brs, NH2-13), 4.24 (1H, dd, J= 6.0, 11.4 Hz,
Ha-3), 4.46 (1H, dd, J= 6.0, 11.4 Hz, Hb-3), 4.78 (1H, d,
J= 6.0, CH2), 6.91 (4H, m, Ar-H), 7.78 (1H, s, NH-12); FTIR
(KBr) cm1: 3052 (‚C–H, aromatic), 1772 (C‚O), 1673
(C‚C), 1259 (–NH2), 1195 (–NH), 758 (C‚C); Anal Calcd.
for C9H10N2O3 (%): C, 55.67; H, 5.19; N, 14.43; O, 24.72.
Found: C, 55.37; H, 5.02; N, 14.67; O, 24.73.2.1.3. Synthesis of 2-(phenyl)-5-(2,3-dihydro-1,4-benzodioxane-
2-yl)-1,3,4-oxadiazole (3a)
A solution of 0.01 mol of 2,3-dihydro-1,4-benzodioxane-2-
carbohydrazide, 0.01 mol benzoic acid and 5 mL of POCl3
was reﬂuxed with stirring for 6–7 h. The reaction mixture
was cooled and poured over crushed ice. The precipitate thus
obtained was ﬁltered washed with sodium bicarbonate, dried
and recrystallised with benzene: methanol. 1H NMR
(300 MHz, DMSO-d6): d ppm 4.33 (2H, m, unresolved
doublet, CH2-3), 5.02 (1H, brs, unresolved doublet, CH-2),
6.88–7.67 (4H, m, Ar-H, ring A), 7.87 (5H, m, Ar-H, ring
B); FTIR (KBr) cm1: 3162 (‚C–H, aromatic), 1678
(C‚C), 1492 (C‚N), 1078 (C–O–C). HR-MS (m/z):
281.1970 [MH]+ (Calcd. for C16H12N2O3, 280.2782); Anal
Calcd. for C16H12N2O3 (%): C, 68.56; H, 4.32; N, 9.99; O,
17.13; Found: C, 68.46; H, 4.42; N, 10.05; O, 17.12.2.1.4. 2-(2-Bromo-phenyl)-5-(2,3-dihydro-1,4-benzodioxane-2-
yl)-1,3,4-oxadiazole (3b)
1H NMR (300 MHz, DMSO-d6): d ppm 4.24 (2H, m, unre-
solved doublet, CH2-3), 5.15 (1H, brs, unresolved doublet,
CH2-2), 6.67–7.91 (4H, m, Ar-H, ring A), 7.65 (5H, m, Ar-
H, ring B); FTIR (KBr) cm1: 3069 (‚C–H, aromatic), 1670
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for C16H11BrN2O3 (%): C, 53.50; H, 3.09; N, 7.80; O, 13.36;
Found: C, 53.43; H, 3.19; N, 7.67; O, 13.43.
2.1.5. 2-(3-Bromo-phenyl)-5-(2,3-dihydro-1,4-benzodioxane-2-
yl)-1,3,4-oxadiazole (3c)
1H NMR (300 MHz, DMSO-d6): d ppm 4.26 (2H, m, unre-
solved doublet, CH2-3), 5.41 (1H, brs, unresolved doublet,
CH2-2), 6.58–7.23 (4H, m, Ar-H, ring A), 7.56 (5H, m, Ar-
H, ring B); FTIR (KBr) cm1: 3106 (‚C–H, aromatic), 1654
(C‚C), 1498 (C‚N), 1053 (C–O–C), 768 (C-Br); Anal Calcd.
for C16H11BrN2O3 (%): C, 53.50; H, 3.09; N, 7.80; O, 13.36:
Found: C, 53.45; H, 3.08; N, 7.84; O, 13.43.
2.1.6. 2-(4-Bromo-phenyl)-5-(2,3-dihydro-1,4-benzodioxane-2-
yl)-1,3,4-oxadiazole (3d)
1H NMR (300 MHz, DMSO-d6): d ppm 4.35 (1H, dd, J= 5.4,
9.9 Hz, CH2-3, H-a), 4.62 (1H, dd, J= 3.3, 3.2 Hz, CH2-3, H-
b), 5.97 (1H, brs, unresolved doublet CH-2), 6.87–7.19 (4H, m,
Ar-H, ring A), 7.47–8.02 (4H, m, Ar-H, ring B); FTIR (KBr)
cm1: 3156 (‚C–H, aromatic), 1687 (C‚C), 1493 (C‚N),
1043 (C–O–C), 746 (C-Br); HRMS (m/z): 359.1955 [M]+
(Calcd. for C16H11BrN2O3, 359.1742). Anal Calcd. for
C16H11BrN2O3 (%): C; 53.50; H, 3.09; Br, 22.25; N, 7.80; O,
13.36. Found: C, 53.48; H, 3.15; N, 7.78; O, 13.26.
2.1.7. 2-(2-Chloro-phenyl)–5-(2,3-dihydro-1,4-benzodioxane-2-
yl)-1,3,4-oxadiazole (3e)
1H NMR (300 MHz, DMSO-d6): d ppm 4.92 (2H, m (unre-
solved doublet), CH2-3), 5.62 (1H, brs, unresolved doublet,
CH-2), 6.74–7.82 (4H, m, Ar-H, ring A), 7.02–7.39 (4H, m,
Ar-H, ring B); FTIR (KBr) cm1: 3197(‚C–H, aromatic),
1648 (C‚C), 1489 (C‚N), 1028 (C–O–C), 745 (C-Cl). Anal
Calcd. for C16H11ClN2O3 (%): C, 61.06; H, 3.52; N, 8.90; O,
15.25; Found: C, 61.12; H, 3.45; N, 8.87; O, 15.29.
2.1.8. 2-(3-Chloro-phenyl)-5-(2,3-dihydro-1,4-benzodioxane-2-
yl)-1,3,4-oxadiazole (3f)
1H NMR (300 MHz, DMSO-d6): d ppm 4.54 (2H, m, unre-
solved doublet, CH-3), 5.22 (1H, brs, unresolved doublet,
CH-2), 6.88–7.57 (4H, m, Ar-H, ring A), 7.23–7.45 (5H, m,
Ar-H, ring B); FTIR (KBr) cm1: 3057 (‚C–H, aromatic),
1643 (C‚C), 1468 (C‚N), 1023 (C–O–C), 768 (C-Cl). Anal
Calcd. for C16H11ClN2O3 (%): C, 61.06; H, 3.52; Cl, 11.26;
N, 8.90; O, 15.25; Found: C, 61.03; H, 3.48; N, 8.78: O, 15.30.
2.1.9. 2-(4-Chloro-phenyl)-5-(2,3-dihydro-1,4-benzodioxane-2-
yl)-1,3,4-oxadiazole (3g)
1H NMR (300 MHz, DMSO-d6): d ppm 4.25 (2H, m, unre-
solved doublet, CH-3), 5.02 (1H, brs, unresolved doublet,
CH2-2), 6.88–7.67 (4H, m, Ar-H, ring A), 7.87 (5H, m, Ar-
H, ring A); FTIR (KBr) cm1: 3158 (‚C–H, aromatic),
1642 (C‚C), 1475 (C‚N), 1016 (C–O–C), 743 (C-Cl) Anal
Calcd. for C16H11ClN2O3 (%): C, 61.06; H, 3.52; Cl, 11.26;
N, 8.90; O, 15.25. Found: C, 60.98; H, 3.48; N, 8.85; O, 15.30.
2.1.10. 2-(2,4-Dichloro-phenyl)-5-(2,3-dihydro-1,4-
benzodioxane-2-yl)-1,3,4-oxadiazole (3h)
1H NMR (300 MHz, DMSO-d6): d ppm 4.35 (2H, m, unre-
solved doublet, CH2-3), 5.91 (1H, brs, unresolved doublet,
CH-2), 6.88–7.07 (4H, m, Ar-H, ring A), 7.73–7.92 (3H, m,
Ar-H, ring B); FTIR (KBr) cm1: 3050 (‚C–H, aromatic),1693 (C‚C), 1478 (C‚N), 1070 (C–O–C), 827, 734 (C-Cl).
Anal Calcd. for C16H10Cl2N2O3 (%): C, 55.04; H, 2.89; Cl,
20.31; N, 8.02; O, 13.75. Found: C, 54.94; H, 2.75; Cl, 20.28;
N, 8.53; O, 13.65.
2.1.11. 2-(2-Methyl-phenyl)-5-(2,3-dihydro-1,4benzodioxane-2-
yl)-1,3,4-oxadiazole (3i)
1H NMR (300 MHz, DMSO-d6): d ppm 2.35 (3H, s, Ar-CH3),
4.52 (2H, m, unresolved doublet, CH2-3), 5.17 (1H, brs, unre-
solved doublet, CH-2), 6.78–7.57 (4H, m, Ar-H, ring A), 7.12–
7.46 (4H, m, Ar-H, ring B); FTIR (KBr) cm1: 3048 (‚C–H,
aromatic), 2970 (Ar-CH3), 1638 (C‚C), 1474 (C‚N), 1025
(C–O–C); Anal Calcd. for C17H14N2O3 (%): C, 69.38; H, 4.79;
N, 9.52; O, 16.31. Found: C, 69.25; H, 4.72; N, 9.54; O, 16.34.
2.1.12. 2-(3-Methyl-phenyl)-5-(2,3-dihydro-1,4-benzodioxane-
2-yl)-1,3,4-oxadiazole (3j)
1H NMR (300 MHz, DMSO-d6): d ppm 2.42 (3H, s, Ar-CH3),
4.41 (1H, dd, J= 5.4, 12.3 Hz, CH2-3, H-a), 4.62 (1H, dd,
J= 2.1, 7.9 Hz, CH2-3, H-b), 5.18 (1H, brs, unresolved dou-
blet CH-2), 6.88–7.01 (4H, m, Ar-H, ring A), 7.25–7.97 (4H,
m, Ar-H, ring B); FTIR (KBr) cm1: 3197 (‚C–H, aromatic),
2950 (Ar-CH3), 1687 (C‚C), 1490 (C‚N), 1076 (C–O–C);
Anal Calcd. for C17H14N2O3(%): C, 69.38; H, 4.79; N, 9.52;
O, 16.31; Found: C, 69.46; H, 4.78; N, 9.49; O, 16.27.
2.1.13. 2-(4-Methyl-phenyl)-5-(2,3-dihydro-1,4-benzodioxane-
2-yl)-1,3,4-oxadiazole (3k)
1H NMR (300 MHz, DMSO-d6): d ppm 2.26 (3H, s, Ar-CH3),
4.27 (2H, m, unresolved doublet, CH2-3), 5.43 (1H, brs, unre-
solved doublet, CH-2), 6.68–7.37 (4H, m, Ar-H, ring A), 7.34–
7.87 (4H, m, Ar-H, ring B); FTIR (KBr) cm1: 3142 (‚C–H,
aromatic), 2850 (Ar-CH3), 1668 (C‚C), 1475 (C‚N), 1038
(C–O–C); Anal Calcd. for C17H14N2O3 (%): C, 69.38; H,
4.79; N, 9.52; O, 16.31; Found: C, 69.42; H, 4.81; N, 9.48;
O, 16.29.
2.1.14. 2-(4-Hydroxy-phenyl)-5-(2,3-dihydro-1,4-
benzodioxane-2-yl)-1,3,4-oxadiazole (3l)
1H NMR (300 MHz, DMSO-d6): d ppm 4.37 (2H, m, unre-
solved doublet, CH2-3), 5.26 (1H, brs, unresolved doublet,
CH-2), 6.88–7.67 (4H, m, Ar-H, ring A), 7.26–7.34 (4H, m,
Ar-H, ring B), 10.24 (1H, s, ArOH); FTIR (KBr) cm1: 3145
(‚C–H, aromatic), 1646 (C‚C), 1479 (C‚N), 1023 (C–O–
C); Anal Calcd. for C16H12N2O4 (%): C, 64.86; H, 4.08; N,
9.46; O, 21.60; Found: C, 64.82; H, 4.25; N, 9.45; O, 21.56.
2.1.15. 2-(3,4-Dihydroxy-phenyl)-5-(2,3-dihydro-1,4-
benzodioxane-2-yl)-1,3,4-oxadiazole (3m)
1H NMR (300 MHz, DMSO-d6): d ppm 4.39 (2H, m (unre-
solved doublet), CH2-3), 5.02 (1H, brs, unresolved doublet,
CH-2), 6.88–7.05 (4H, m, Ar-H, ring A), 6.26–7.12(3H, m,
Ar-H, ring B), 10.36 (2H, s, Ar-OH); FTIR (KBr) cm1: 3042
(‚C–H, aromatic), 1648 (C‚C), 1469 (C‚N), 1048 (C–O–
C); Anal Calcd. for C16H11N2O5 (%): C, 61.54; H, 3.87; N,
8.97; O, 25.62; Found: C, 61.58; H, 3.85; N, 8.89; O, 25.59.
2.1.16. 2-(4-Methoxy-phenyl)-5-(2,3-dihydro-1,4-
benzodioxane-2-yl)-1,3,4-oxadiazole (3n)
1H NMR (300 MHz, DMSO-d6): d ppm 3.84 (3H, s, Ar-
OCH3), 4.62 (2H, m, unresolved doublet, CH2-3), 5.87 (1H,
Scheme 1 Synthetic route for the preparation of 1,3,4-oxadiazole derivatives (3a–p).
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A), 7.92–7.94 (4H, m, Ar-H, ring B); FTIR (KBr) cm1: 3062
(‚C–H, aromatic), 1611 (C‚C), 1494 (C‚N), 1180, 1017 (C–
O–C); Anal Calcd. for C17H14N2O4 (%): C, 65.80; H, 4.55; N,
9.03; O, 20.62; Found: C, 65.78; H, 4.58; N, 9.13; O, 20.69.
2.1.17. 2-(3,4-Dimethoxy-phenyl)-5-(2,3-dihydro-1,4-
benzodioxane-2-yl)-1,3,4-oxadiazole (3o)
1H NMR (300 MHz, DMSO-d6): d ppm 3.76 (2H, s, Ar-
OCH3), 4.52 (2H, m, unresolved doublet, CH2-3), 5.35 (1H,
brs, unresolved doublet, CH-2), 6.88–7.67 (4H, m, Ar-H, ring
A), 7.01–7.32 (3H, m, Ar-H, ring B); FTIR (KBr) cm1: 3067
(‚C–H, aromatic), 1664 (C‚C), 1469 (C‚N), 1245, 1030,
1024 (C–O–C); Anal Calcd. for C18H16N2O5 (%): C, 63.52;
H, 4.74; N, 8.23; O, 23.51; Found: C, 63.48; H, 4.79; N,
8.26; O, 23.49.Table 1 Chemical structures, melting point and percentage yield of
S. No. Compd. R
1 3a H
2 3b 2-Bromo
3 3c 3-Bromo
4 3d 4-Bromo
5 3e 2-Chloro
6 3f 3-Chloro
7 3g 4-Chloro
8 3h 2,4-Dichloro
9 3i 2-Methyl
10 3j 3-Methyl
11 3k 4-Methyl
12 3l 4-Hydroxy
13 3m 3,4-Dihydroxy
14 3n 4-Methoxy
15 3o 3,4-Dimethoxy
16 3p 4-Amino2.1.18. 2-(4-Amino-phenyl)-5-(2,3-dihydro-1,4-benzodioxane-
2-yl)-1,3,4-oxadiazole (3p)
1H NMR (300 MHz, DMSO-d6): d ppm 4.35 (2H, s, Ar-NH2),
4.61 (2H, m (unresolved doublet), CH2-3), 5.25 (1H, brs, unre-
solved doublet, CH-2), 6.73–7.21 (4H, m, Ar-H, ring A), 7.66–
8.15 (4H, m, Ar-H, ring B); FTIR (KBr) cm1: 3072 (‚C–H,
aromatic), 1648 (C‚C), 1449 (C‚N), 1320 (C–N), 1036
(C–O–C); Anal Calcd. for C16H13N3O3 (%): C, 65.08; H, 4.44;
N, 14.23; O, 16.25; Found: C, 65.10; H, 4.45; N, 14.24; O, 16.21.
2.2. Experimental determination of antibacterial
and antifungal activities
The minimal inhibitory concentrations (MIC50) of the title
compounds were determined in vitro by the modiﬁed micro-
broth dilution method according to the methods deﬁned bythe synthesized 1,3,4-oxadiazole derivatives (3a–p).
Molecular formula m.p. (C) Yield (%)
C16H12N2O3 160–62 76
C16H11BrN2O3 175–77 68
C16H11BrN2O3 156–58 72
C16H11BrN2O3 135–37 75
C16H11ClN2O3 189–91 69
C16H11ClN2O3 201–203 82
C16H11ClN2O3 182–84 73
C16H10Cl2N2O3 148–150 79
C17H18N2O4 139–41 70
C17H14N2O3 134–36 81
C17H14N2O3 142–44 77
C16H12N2O4 128–30 64
C16H11N2O5 165–67 65
C17H14N2O4 87–89 71
C18H16N2O5 141–43 74
C16H13N3O3 55–57 67
Table 2 Antibacterial and antifungal data as MIC (lg/mL) for oxadiazole derivatives (3a–p).a,b
Compd. R Antibacterial activity Antifungal activity
S. aureus E. coli B. subtilis A. niger A. ﬂavus C. albicans
3a H 32 16 32 64 64 >32
3b 2-Br 8 16 8 32 32 >32
3c 3-Br 4 4 8 64 64 >16
3d 4-Br 0.25 0.25 0.5 32 >32 64
3e 2-Cl 4 4 16 16 >16 >16
3f 3-Cl 8 8 8 16 16 >32
3g 4-Cl 0.5 >0.25 0.5 32 32 >32
3h 2,4-Cl 0.5 1 0.5 1 16 32
3i 2-CH3 32 32 64 32 >64 64
3j 3-CH3 32 64 64 16 8 16
3k 4-CH3 32 64 >32 16 16 32
3l 4-OH 32 64 >16 32 32 128
3m 3,4-OH 16 8 8 8 8 12
3n 4-OCH3 8 16 16 32 16 32
3o 3,4-OCH3 8 16 16 16 8 8
3p 4-NH2 32 64 16 64 32 64
Norﬂoxacin 0.25 0.5 1 – – –
Chloramphenicol 8 8 16 – – –
Fluonazole – – – 16 8 16
a Minimum inhibitory concentrations were determined by micro-broth dilution method.
b S. aureus, Staphylococcus aureus NCIM 2079; B. subtilis, Bacillus subtilis NCIM 2439; E. coli, Escherichia coli NCIM 5051; A. niger,
Aspergillus niger ATCC 1034; A. ﬂavus, Aspergillus ﬂavus MTCC 2799; C. albicans, Candida albicans, ATCC 753.
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The test strains were provided by the National chemical Lab-
oratory, Pune. The prepared compounds were evaluated for
their antibacterial activity against S. aureus NCIM 2079 and
Bacillus subtilis NCIM 2439 as Gram-positive, Escherichia coli
NCIM 5051 as Gram-negative bacteria. The bacterial suspen-
sion was adjusted with sterile saline to a concentration of
1 · 105 CFU. The test compounds were dissolved in dimethyl
sulfoxide (DMSO) to prepare the stock solutions. The test
compounds and reference drugs were prepared by twofold
serial dilution to obtain the required concentrations of 512,
256, 128, 64, 32, 16, 8, 4, 2, 1, 0.5 and 0.25 lg/mL. These dilu-
tions were inoculated and incubated at 37 C for 24 h. To en-
sure that the solvent had no effect on bacterial growth, a
control test was performed with test medium supplemented
with DMSO at the same dilutions as used in the experiment.
The new compounds were evaluated for their antifungal activ-
ity against Aspergillus niger ATCC 1034, A. ﬂavusMTCC 2799
and Candida albicans ATCC 753. A spore suspension in sterile
distilled water was prepared from 1-day old culture of the
fungi growing on Sabouraud agar (SA) media. The ﬁnal spore
concentration was 1–5 · 103 spore mL1. From the stock solu-
tions of the tested compounds and reference antifungal ﬂuco-
nazole, dilutions in sterile RPMI 1640 medium were made
resulting in concentrations (0.25–512 lg/mL) of each testedcompound. These dilutions were inoculated and incubated at
35 C for 24 h. The drug MIC50 was deﬁned as the ﬁrst well
with an approximate 50% reduction in growth compared to
the growth of the drug-free well.
3. Result and discussion
The synthetic route used to prepare starting materials and the
title compounds is outlined in Scheme 1. The starting material
ethyl-l,4-benzodioxane-2-carboxylate (1) was prepared by reac-
tion between catechol and ethyl-2,3-dibromopropionate in dry
acetone in the presence of anhydrous potassium carbonate,
which on treatment with hydrazine hydrate afforded the corre-
sponding hydrazide (2). The reaction of hydrazide (2) with
substituted aryl carboxylic acids in phosphorus oxychloride
(POCl3) gave the cyclized products 2-(substituted-phenyl)-5-
(2,3-dihydro-1,4-benzodioxane-2-yl)-1,3,4-oxadiazoles (3a–
p). Chemical structures, melting point and percentage yield of
the synthesized compounds were reported in Table 1. The syn-
thesized compounds were characterized by 1HNMR,Mass and
IR spectroscopical data and elemental analysis.
The IR spectrum of compound 1 showed an intense peak at
1772 cm1 for carbonyl C‚O; 1653 cm1 for C‚C; 3052 cm1
for‚C–H; and 1292 cm1 for C–O ester groups. The 1HNMR
spectrumof 1 showed a triplet at d 1.23 (J= 7.1 Hz) and a quar-
S1034 H. Khalilullah et al.tet at d 4.20 (J= 7.1, 5.7 Hz) due to –CH3 at position 12 and
CH2– at position 13, respectively. A triplet at d 4.77 and a dou-
blet at d 4.3 were assigned to the protons of CH2– at positions 2
and 3. Aromatic protons appeared as multiplets at d 6.84–7.22.
The IR spectrum of compound 2 showed an intense peak at
1725 cm1 for carbonyl C‚O, 1642 cm1 for C‚C, 3045 cm
1 for ‚C–H aromatic ring. The 1H NMR spectrum of 2
showed two double doublets at d 4.24 and 4.46 (J= 6.0) corre-
sponding toC-Ha andC-Hb of position 2, a doublet at d 4.78was
assigned to the protons of CH2 at position 3, Two protons of
NH2– at position 13 were appeared as a broad singlet at d 3.91
and a proton as a singlet at d 7.78 (J= 7.5) was assigned to
the protons of NH– at position 12. Aromatic protons were ap-
peared as multiplets at d 6.91 ppm. The compound 3a showed
peaks at 3162 for‚C–H, aromatic ring), 1678 for C‚C, 1492
for C‚N and 1078 for C–O–C. The 1H NMR spectrum of 3a
showed two protons of CH2 at positions 2 and 3 as multiplets
(unresolved doublet) at d 4.33 and 5.02, respectively. Aromatic
protons of ring A were appeared as multiplets at d 6.88–7.67.
Aromatic protons of ring B were located at d 7.87. The mass
spectrum of the title compounds is in conformity with the as-
signed structures. Themass spectra of these compounds showed
molecular ion peaks corresponding to their molecular formulae.
All of the synthesized compounds were screened in vitro for
antibacterial activities against Gram-positive S. aureus and B.
subtilis and Gram-negative E. coli as well as antifungal activi-
ties against A. niger, A. ﬂavus and C. albicans by twofold serial
dilution technique (Kadi et al., 2007 Ozbek et al., 2007). All
compounds were evaluated at the concentrations of the antimi-
crobial agents ranging from 0.25 to 512 lg/mL and scored for
MIC50 as the level of growth inhibition of the microorganisms
compared with that of the current antimicrobial drugs ﬂuco-
nazole, chloramphenicol and norﬂoxacin in clinic. The data
of antibacterial and antifungal tests are depicted in Table 2.
The obtained results showed that the synthesized com-
pounds 3a–p exhibited moderate to excellent activities against
all tested strains. As noted in Table 2, compound 3d, 3g, 3h
have shown excellent antibacterial activities against both the
Gram-positive strains S. aureus and B. subtilis and Gram neg-
ative E. coli with MIC values of 0.25–1 lg/mL. Antimicrobial
activity data revealed that the presence of electron withdraw-
ing group in aromatic ring of 1,3,4-oxadiazole ring improved
the activity; however, a more lipophilic group at the same po-
sition greatly enhanced the antifungal activities of the synthe-
sized azole derivatives.4. Conclusion
In conclusion, a series of 1,4-benzodioxane-based azole deriv-
atives were designed and synthesized for the ﬁrst time via an
easy, convenient and efﬁcient synthetic route. The antimicro-
bial results showed that azole in combination with 1,4-benzo-
dioxane is a promising template for antibacterial and
antifungal activities.Acknowledgements
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